Member Info for inanaco

post rec.

we have two events before that

Grand Challenge and BioNtech TCR

Best of luck ..

you do understand Val does not have any lab equipment ?

The additional information required for the expanded Final Trial Management documentation, including the Investigational Brochure, the Investigational Medicinal Product Dossier and Clinical Trial Application for the new trial, are now being completed so that all remaining permissions and approvals are obtained for this trial to commence in """Q1 2014."""

""" The expanded trial is anticipated to yield early results within 8 weeks of commencement."""""

these waffle RNS .. have been on going for years ..

remember YODA and his Fast track Speedy Trials .. every other word he posted was accelerated ...

2015 RNS

With this result, the trial will advance to the next elevation of dose, where further safety and tolerability testing will be undertaken and early stage efficacy will continue to be investigated as the trial progresses. The trial is directed towards providing information on the maximum applicable dose level possible.

2016 end of year

 Phase l/ll Clinical Trial of VAL201 has confirmed that compound is well tolerated up to a putative therapeutic dose and has shown a high degree of safety, with no significant adverse events being reported

Expansion of VAL201 trial into a multi-centre study ???? what happened to that ??

putative
/ˈpjuːtətɪv/Submit
adjective
generally considered or reputed to be.

that didn't work did it ....

2017

yet another dose increase in January ....

Dr Satu Vainikka, CEO of ValiRx, commented: "VAL201 has demonstrated disease stabilisation, with a lower dose than was predicted by our preclinical evaluations. We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and tolerability shown to date to meet the needs of those patients currently under-served by current therapies. ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value".

By Dec 2017 yet another dose increase ....

·     To substantially raise the dosing level in patients in order to reach therapeutic levels and reduce disease progression;Â

Last years RNS the most important bit

"""To substantially raise the dosing level in patients in order to reach therapeutic levels and reduce disease progression""

"""""""""" to reach therapeutic levels """"""""""""""

value is in 201 .. which is subject to a dose escalation phase, in 6 patients I believe . so if they get to "commercial "efficacy in this cohort, then this needs to be expanded to 30 to 50 patients, it would be better done at this stage while the trial is ongoing, as it will be difficult to present quality data on only 6 patients to interested parties, so you need another big dilution to get you over the line however it will be based on "UK quality" data rather than this cobbled together data set from Val 401

if no commercial efficacy its game over ...

two together is a roll over ... as 874,000 shared dumped would have crashed the price why would a MM take them on with only .2 on the spread

then offer 7.8 2 mins later against 7.9

the question you need to ask is what other drugs are patients given at End Stage ... the main drug is Morphine for pain relief, patients would be long term users so would be already addicted to morphine which can induce psychosis. As 401 is actually a antipsychotic drug, its acting in concert with morphine, so you would need a proof trial that Val401 was not mimicking Risperidone if you are marketing as an end stage palliative care treatment ..

and its only treated 7 patients ... ?

but that only meets two of the criteria ... ie you get inside two types of cell

the third is inflammation or the use of an adjuvant

GENE DELIVERY

Direct gene transfer for the treatment of human diseases requires a vector which can be administered efficiently, safely and repeatedly. Nanovesicles represent one of the few examples that can meet these requirements. Our TRANSFECTOSOMES form stable complex nanovesicles with DNA/RNA and rapidly release the DNA/RNA into the cells by endocytosis.

its possible to do it this way

Endocytosis is a cellular process in which substances are brought into the cell. The material to be internalized is surrounded by an area of plasma membrane, which then buds off inside the cell to form a vesicle containing the ingested material. Endocytosis includes pinocytosis (cell drinking) and phagocytosis (cell eating).

its a speculation .. non of us know ..

but we do know what Ichor has to achieve, to induce vaccination

well somehow you have to fire these nanovesicles into a cell ... and indeed Dendritic cells as well otherwise you will not get the cross presentation .. so the cell wall is opened by high speed nano particles or electricity ichor ... IMHO

I put in another £994 earlier, thats £3000 this week, fast approaching 700,000 .. and why not, who else has data like this ? mad not to keep buying at this level ...

The market panics over a month or two delay with SCIB1

and ignores Modi2 and Clycans ...

Crumbs i took the info ref Ichor from Bobs post, as per AGM recording yes we are switching to a new device for SCIB2

That came out of the AGM is modi2 ......

we all thought Modi1 could not be improved upon .. indeed it produces startling results in the mouse model and those patients that might fall throw the Net can possibly access BioNtech TCR

Modi1 needs inflammation to get the cancer to express the citrullinated epitope, inflammation induces stress so the action of the vaccine continues to infame the cancer so that the expression continues to destruction

Then out comes Modi2 ... able to break tolerance of cold cancers (cancer without inflammation) ....so if patients again fall through Modi 1 ... they can receive Modi2 and indeed have yet another fall back of BioNtech TCR as this is also being looked at (if i get that right from AGM) Or Modi2 can be added to Modi1 if the cancers managed to suppress the modi1 vaccine like a booster ...

which Brings me to Modi3 ..... Lindy has laid out with Modi2 all the technology and criteria to deal with cold cancers
because this is a new patent ... i am actually wondering if Scancell itself delayed the presentation to the Grand Challenge (Nov to Jan) to allow this information which is astonishing to be released to the public via the Grand Challenge as soon as they had announced to the market and protected it via the Patent application

we really are set up now ... all the possible delays to trials identified and being sorted...

Thanks for the update

Crumbs a hint that all work is being done by CRUK ... well, they will not be developing a new SCib1 ... its an ichor deal IMHO ..

its an Olympic sport ... spitting dummies

depends who survives the Riot .. LOL

https://blog.dana-farber.org/insight/2018/06/enhancing-immunotherapy-race-make-cold-tumors-hot/